30 September 2026
30 September 2026
Participants receiving Foundayo lost 1.5% more body weight on average than those taking oral semaglutide.
The agreement grants Knight Therapeutics rights to market the medicine for mycosis fungoides and Sézary syndrome subtypes.
The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan.
The trial enrolled patients with presumed or confirmed viral or bacterial pneumonia who needed additional oxygen support.
The state expects the initiative to generate 205 jobs and yield an economic impact exceeding $1.5bn across a ten-year span.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
